is there still a glp-1 shortage FDA's decision kicks off 'unprecedented' tussle over glp-1 drug shortages A Major

[14] reported that exenatide did not alter total peripheral resistance or diastolic blood pressure, which does not support the reflex tachycardia hypothesis

The highest return on capital over the next decade will likely sit with the owners of the difficult parts of the chain: the innovators with next-gen IP and the specialized manufacturers (CDMOs/Device Makers) who can solve the persistent fill-finish bottleneck

For tirzepatide, evidence of renal benefit derives primarily from post hoc analyses of the SURPASS program and meta-analyses [20,21,22], demonstrating dose-dependent reductions in albuminuria and slower eGFR decline compared with insulin glargine

Your GI and General Surgeons are Key